{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:38:28Z","timestamp":1786984708067,"version":"build-2736575974"},"reference-count":121,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.arbres.2015.04.016","type":"journal-article","created":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T20:59:44Z","timestamp":1436907584000},"page":"36-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Documento de consenso sobre la prevenci\u00f3n y el tratamiento de la tuberculosis en pacientes candidatos a tratamiento biol\u00f3gico"],"prefix":"10.1016","volume":"52","author":[{"given":"Isabel","family":"Mir Viladrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Daud\u00e9n Tello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Solano-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"L\u00f3pez Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Taxonera Samso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paquita","family":"S\u00e1nchez Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mart\u00ednez Lacasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Garc\u00eda Gasalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Dorca Sargatal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Arias-Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Maria","family":"Garc\u00eda Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2015.04.016_bib0610","unstructured":"Infliximab approval process in Crohn's disease. Department of Health and Human Services. Public Health Service. Food and Drug Administration August 24, 1998."},{"issue":"Suppl 1","key":"10.1016\/j.arbres.2015.04.016_bib0615","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ard.2009.123885","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009","volume":"69","author":"Furst","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib0620","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2015.04.016_bib0625","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arbres.2015.04.016_bib0630","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0210-5705(03)70338-0","article-title":"Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab. Spanish Working Group on Crohn Disease and Ulcerative Colitis","volume":"26","author":"Obrador","year":"2003","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.arbres.2015.04.016_bib0635","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib0640","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arbres.2015.04.016_bib0645","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.crohns.2012.05.012","article-title":"Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening","volume":"7","author":"Jauregui-Amezaga","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.arbres.2015.04.016_bib0650","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinids\/18.3.421","article-title":"Purpose of quality standards for infectious diseases","volume":"18","author":"Gross","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib0655","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonists mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Therapeut"},{"key":"10.1016\/j.arbres.2015.04.016_bib0660","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.autrev.2009.01.012","article-title":"Interleukin-6 as a key player in systemic inflammation and joint destruction","volume":"8","author":"Fonseca","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.arbres.2015.04.016_bib0665","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1741-7015-11-88","article-title":"Biologic therapy for autoimmune diseases: An update","volume":"11","author":"Rosman","year":"2013","journal-title":"BMC Medicine"},{"key":"10.1016\/j.arbres.2015.04.016_bib0670","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2172-14-34","article-title":"CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients","volume":"14","author":"Pieper","year":"2013","journal-title":"BMC Immunol"},{"key":"10.1016\/j.arbres.2015.04.016_bib0675","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.arbres.2015.04.016_bib0680","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2015.04.016_bib0685","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","article-title":"Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arbres.2015.04.016_bib0690","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"ArthritisRheum"},{"key":"10.1016\/j.arbres.2015.04.016_bib0695","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3899\/jrheum.121376","article-title":"Hand bone loss in patients with psoriatic arthritis: Posthoc analysis of IMPACT II data comparing infliximab and placebo","volume":"40","author":"Hoff","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.arbres.2015.04.016_bib0700","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"Van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arbres.2015.04.016_bib0705","first-page":"5","article-title":"Efficacy of infliximab in refractory Beh\u00e7et's disease-associated and idiopathic posterior segmentuveitis: A prospective, follow-up study of 50 patients","volume":"6","author":"Cantini","year":"2012","journal-title":"Biologics"},{"key":"10.1016\/j.arbres.2015.04.016_bib0710","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","article-title":"Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease","volume":"130","author":"Okada","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.arbres.2015.04.016_bib0715","first-page":"32","article-title":"Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience","volume":"59","author":"Moreland","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arbres.2015.04.016_bib0720","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.21885","article-title":"Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis","volume":"54","author":"Lovell","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arbres.2015.04.016_bib0725","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arbres.2015.04.016_bib0730","first-page":"1","volume":"0","author":"Horneff","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib0735","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/rheumatology\/keh475","article-title":"Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis","volume":"44","author":"Brandt","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.arbres.2015.04.016_bib0740","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/ard.2003.016014","article-title":"A multicenter double-blind randomized placebo-controlled trial of Kineret* (anakinra), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate therapy","volume":"63","author":"Cohen","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib0745","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody for the treatment of RA in patients taking concomitant methotrexate. The ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arbres.2015.04.016_bib0750","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER Study: Combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in methotrexate-na\u00efve patients with early, aggressive rheumatoid arthritis","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arbres.2015.04.016_bib0755","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2015.04.016_bib0760","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. ADEPT","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arbres.2015.04.016_bib0765","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Long-term efficacy and safety in Ankylosing Spondylitis Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ATLAS)","volume":"54","author":"Van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arbres.2015.04.016_bib0770","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/annrheumdis-2012-201324","article-title":"Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: The MIRAR Study","volume":"71","author":"Gomez-Reino","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib0775","first-page":"15","article-title":"Rituximab en el lupus eritematoso sist\u00e9mico y otras enfermedades autoinmunes","volume":"9","author":"L\u00f3pez-Longo","year":"2008","journal-title":"Med Clin Monogr (Barc)"},{"key":"10.1016\/j.arbres.2015.04.016_bib0780","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1177\/0961203312446627","article-title":"Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: The LESIMAB study","volume":"21","author":"Fernandez-Nebro","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.arbres.2015.04.016_bib0785","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2015.04.016_bib0790","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2015.04.016_bib0795","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3899\/jrheum.120447","article-title":"Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results","volume":"40","author":"Fleischmann","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.arbres.2015.04.016_bib0800","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2015.04.016_bib0805","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2015.04.016_bib0810","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/annrheumdis-2012-201697","article-title":"Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab","volume":"72","author":"Wagner","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib0815","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/annrheumdis-2012-203075","article-title":"The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: Results through 4 years of the GO-RAISE trial","volume":"73","author":"Braun","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.arbres.2015.04.016_bib0820","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/acr.20331","article-title":"American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: Data from a 52-week phase III trial","volume":"63","author":"Van Vollenhoven","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.arbres.2015.04.016_bib0825","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/art.37995","article-title":"Baseline predictors of systemic lupus erythematosus flares: Data from the combined placebo groups in the phase III Belimumab trials","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arbres.2015.04.016_bib0830","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.arbres.2015.04.016_bib0835","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulising Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2015.04.016_bib0840","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1572-0241.2003.04010.x","article-title":"Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries","volume":"99","author":"Lichtenstein","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.arbres.2015.04.016_bib0845","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2005.01.048","article-title":"Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulising Crohn's disease","volume":"128","author":"Lichtenstein","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.arbres.2015.04.016_bib0850","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/j.1572-0241.2003.07674.x","article-title":"The effects of infliximab maintenance therapy on health-related quality of life","volume":"98","author":"Feagan","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.arbres.2015.04.016_bib0855","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","article-title":"Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease","volume":"63","author":"Rutgeerts","year":"2006","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.arbres.2015.04.016_bib0860","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2015.04.016_bib0865","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1572-0241.2007.01094.x","article-title":"The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients","volume":"102","author":"Feagan","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.arbres.2015.04.016_bib0870","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.arbres.2015.04.016_bib0875","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis","volume":"10","author":"Hyams","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.arbres.2015.04.016_bib0880","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1053\/j.gastro.2008.10.051","article-title":"Infliximab prevents Crohn's disease recurrence after ileal resection","volume":"136","author":"Regueiro","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.arbres.2015.04.016_bib0885","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.crohns.2013.02.018","article-title":"Long term benefit of one year infliximab administration for the treatment of chronic refractory pouchitis","volume":"7","author":"Viazis","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.arbres.2015.04.016_bib0890","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenence treatment of Crohn's disease: Results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.arbres.2015.04.016_bib0895","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.arbres.2015.04.016_bib0900","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1053\/j.gastro.2008.07.069","article-title":"Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.arbres.2015.04.016_bib0905","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: Data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.arbres.2015.04.016_bib0910","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.arbres.2015.04.016_bib0915","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.arbres.2015.04.016_bib0920","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2013.09.032","article-title":"Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.arbres.2015.04.016_bib0925","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.arbres.2015.04.016_bib0930","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/ajg.2013.287","article-title":"Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: A randomized controlled trial","volume":"108","author":"Savarino","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.arbres.2015.04.016_bib0935","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.arbres.2015.04.016_bib0940","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.arbres.2015.04.016_bib0945","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2015.04.016_bib0950","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2015.04.016_bib0955","unstructured":"European Medicines Agency. Ficha t\u00e9cnica de Humira (adalimumab) [consultado 29 Oct 2013]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000481\/WC500050870.pdf"},{"key":"10.1016\/j.arbres.2015.04.016_bib0960","unstructured":"European Medicines Agency. Ficha t\u00e9cnica de Enbrel (etanercept) [consultado 29 Oct 2013]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000262\/WC500027361.pdf"},{"key":"10.1016\/j.arbres.2015.04.016_bib0965","unstructured":"European Medicines Agency. Ficha t\u00e9cnica de Remicade (infliximab) [consultado 29 Oct 2013]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000240\/WC500050888.pdf"},{"key":"10.1016\/j.arbres.2015.04.016_bib0970","unstructured":"European Medicines Agency. Ficha t\u00e9cnica de Stelara (ustekinumab) [consultado 29 Oct 2013]. Disponible en:http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000958\/WC500058513.pdf"},{"key":"10.1016\/j.arbres.2015.04.016_bib0975","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1586\/17469872.2013.814880","article-title":"Etanercept for the treatment of psoriasis","volume":"8","author":"Ara","year":"2013","journal-title":"Expert Rev Dermatol"},{"key":"10.1016\/j.arbres.2015.04.016_bib0980","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1610-0387.2007.06319.x","article-title":"The use of infliximab in dermatology","volume":"5","author":"Rott","year":"2007","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.arbres.2015.04.016_bib0985","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.sder.2010.02.004","article-title":"The future of biological therapies","volume":"29","author":"Warren","year":"2010","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.arbres.2015.04.016_bib0990","doi-asserted-by":"crossref","first-page":"e51819","DOI":"10.1371\/journal.pone.0051819","article-title":"Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity","volume":"7","author":"Tsuda","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.arbres.2015.04.016_bib0995","first-page":"1127","article-title":"TB in patients receiving anti-TNF agents despite chemoprophylaxis","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib1000","doi-asserted-by":"crossref","DOI":"10.1002\/art.11134","article-title":"TB in the cytokine era: What rheumatologist need to know","volume":"48","author":"Hamilton","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arbres.2015.04.016_bib1005","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.eimc.2012.06.014","article-title":"Use of Quantiferon-TB-Gold in Tube\u00ae test for detecting latent tuberculosis in patients considered as candidates for anti-TNF therapy in routine clinical practice","volume":"31","author":"Garc\u00eda-Gasalla","year":"2013","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.arbres.2015.04.016_bib1010","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2004.029041","article-title":"Attenuated response to purified protein derivative in patients with rheumatoid arthritis: Study in a population with a high prevalence of tuberculosis","volume":"64","author":"Ponce de Leon","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib1015","first-page":"776","article-title":"Comparison of an interferon-\u03b3 assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population","volume":"35","author":"Ponce de Leon","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.arbres.2015.04.016_bib1020","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/clinids\/17.6.968","article-title":"The tuberculin skin test","volume":"17","author":"Huebner","year":"1993","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib1025","unstructured":"Cellestis. Quantiferon-TB Gold. 2009 [consultado 20 Oct 2009]. Disponible en: http:\/\/www.cellestis.com\/"},{"key":"10.1016\/j.arbres.2015.04.016_bib1030","unstructured":"Oxford Immunotec. T.Spot-TB. 2009 [consultado 20 Oct 2009]. Disponible en: http:\/\/www.oxfordimmunotec.com\/"},{"key":"10.1016\/j.arbres.2015.04.016_bib1035","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1128\/CVI.00364-07","article-title":"Comparison of two commercially available gamma-interferon blood tests for immunodiagnosis of tuberculosis","volume":"15","author":"Dominguez","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.arbres.2015.04.016_bib1040","first-page":"1","article-title":"Updated guidelines for using interferon g release assays to detect Mycobacterium tuberculosis infection \u2014 United States, 2010","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.arbres.2015.04.016_bib1045","unstructured":"European Centre for Disease Prevention and Control (ECDC). Use of interferon-gamma release assays in support of TB diagnosis [consultado Jul 2013]. Disponible en: http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/1103_GUI_IGRA.pdf"},{"key":"10.1016\/j.arbres.2015.04.016_bib1050","doi-asserted-by":"crossref","first-page":"e32482","DOI":"10.1371\/journal.pone.0032482","article-title":"Interferon-\u03b3 release assay for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: A systematic review and meta-analysis","volume":"7","author":"Santin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.arbres.2015.04.016_bib1055","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1157\/13126836","article-title":"Normativa SEPAR. Diagn\u00f3stico y tratamiento de la tuberculosis","volume":"44","author":"Ruiz Manzano","year":"2008","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2015.04.016_bib1060","first-page":"770","article-title":"Comparison of an in vitro tuberculosis interferon-\u03b3 assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis","volume":"35","author":"Greenberg","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.arbres.2015.04.016_bib1065","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3899\/jrheum.090268","article-title":"Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"36","author":"Inanc","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.arbres.2015.04.016_bib1070","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10096-008-0519-1","article-title":"Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment","volume":"27","author":"Bocchino","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib1075","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/rheumatology\/kem064","article-title":"Use of QuantiFERON TB Gold test as a part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: The Newcastle (UK) experience","volume":"46","author":"Pratt","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.arbres.2015.04.016_bib1080","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00296-007-0361-2","article-title":"Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration","volume":"27","author":"Takahashi","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.arbres.2015.04.016_bib1085","first-page":"1464","article-title":"Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment","volume":"35","author":"Vassilopoulos","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.arbres.2015.04.016_bib1090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","article-title":"Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases performance of a Mycobacterium tuberculosis antigen specific IFN-gamma assay","volume":"67","author":"Matulis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib1095","first-page":"117","article-title":"Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers","volume":"11","author":"Cobanoglu","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib1100","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1136\/ard.2007.069799","article-title":"Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy","volume":"66","author":"Sellam","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib1105","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1586\/ers.09.20","article-title":"IFN-gamma release assay to diagnose TB infection in the immunocompromised individual","volume":"3","author":"Dominguez","year":"2009","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.arbres.2015.04.016_bib1110","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1164\/rccm.200811-1704OC","article-title":"Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing","volume":"180","author":"Van Zyl-Smit","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2015.04.016_bib1115","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-3083.2008.02103.x","article-title":"The tuberculin skin test increases the responses measured by T cell interferon-gamma release assays","volume":"67","author":"Vilaplana","year":"2008","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.arbres.2015.04.016_bib1120","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/apt.12037","article-title":"Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-a inhibitors","volume":"36","author":"Papay","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.arbres.2015.04.016_bib1125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/annrheumdis-2011-200489","article-title":"Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFa inhibitors: The utility of IFNg assay","volume":"71","author":"Chen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib1130","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1186\/ar3882","article-title":"Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor-alpha antagonists","volume":"14","author":"Hatemi","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"4 Pt 2","key":"10.1016\/j.arbres.2015.04.016_bib1135","first-page":"S221","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2015.04.016_bib1140","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMcp1005750","article-title":"Clinical practice. Latent tuberculosis infection in the United States","volume":"364","author":"Horsburgh","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2015.04.016_bib1145","first-page":"735","article-title":"Update: Adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection\u2014United States, 2003","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.arbres.2015.04.016_bib1150","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis","volume":"60","year":"1982","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.arbres.2015.04.016_bib1155","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib1160","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatotoxicity associated with isoniazid preventive therapy: A 7-year survey from a public health tuberculosis clinic","volume":"281","author":"Nolan","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.arbres.2015.04.016_bib1165","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1164\/ajrccm.155.5.9154885","article-title":"Rifampin preventive therapy for tuberculosis infection: Experience with 157 adolescents","volume":"155","author":"Villarino","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2015.04.016_bib1170","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","article-title":"Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: A randomized trial","volume":"149","author":"Menzies","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.arbres.2015.04.016_bib1175","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5588\/ijtld.12.0510","article-title":"Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population","volume":"17","author":"Jim\u00e9nez-Fuentes","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib1180","doi-asserted-by":"crossref","first-page":"e36001","DOI":"10.1371\/journal.pone.0036001","article-title":"The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: A trial-based analysis","volume":"7","author":"Pho","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.arbres.2015.04.016_bib1185","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5114\/aoms.2013.33352","article-title":"Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-\u03b1 agents","volume":"9","author":"Paluch-Ole\u015b","year":"2013","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.arbres.2015.04.016_bib1190","first-page":"C4480","article-title":"Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment","volume":"59","author":"Nordgaard-Lassen","year":"2012","journal-title":"Dan Med J"},{"key":"10.1016\/j.arbres.2015.04.016_bib1195","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/thorax.57.9.804","article-title":"A meta-analysis of the effect of Bacille Calmette Gu\u00e9rin vaccination on tuberculin skin test measurements","volume":"57","author":"Wang","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2015.04.016_bib1200","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.diagmicrobio.2010.12.020","article-title":"Diagnosis of tuberculosis infection by tuberculin skin test and a whole-blood interferon-(release assay in patients considered for anti-tumor necrosis factor-\u03b1 therapy","volume":"71","author":"Casas","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib1205","first-page":"19","article-title":"Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review","volume":"10","author":"Fraser","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.arbres.2015.04.016_bib1210","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1136\/annrheumdis-2012-201979","article-title":"You can\u2019t always get what you want, but if you try sometimes (with two tests\u2014TST and IGRA\u2014for tuberculosis) you get what you need","volume":"71","author":"Winthrop","year":"2012","journal-title":"Ann Rheum Dis"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289615002045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289615002045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T19:26:29Z","timestamp":1537471589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289615002045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0300289615002045"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2015.04.016","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Documento de consenso sobre la prevenci\u00f3n y el tratamiento de la tuberculosis en pacientes candidatos a tratamiento biol\u00f3gico","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2015.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 SEPAR. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}